{"id":2152,"date":"2012-01-24T00:59:32","date_gmt":"2012-01-24T00:59:32","guid":{"rendered":"http:\/\/africa-and-science.com\/?p=2152"},"modified":"2012-01-31T21:19:36","modified_gmt":"2012-01-31T21:19:36","slug":"hiv-aids-vaccine-will-be-available-in-the-nearest-future","status":"publish","type":"post","link":"https:\/\/africa-and-science.com\/?p=2152","title":{"rendered":"HIV-AIDS vaccine will be available in the nearest future"},"content":{"rendered":"

\"\"<\/a>According to information made available by canadian media recently, researchers are now heading towards a vaccine.<\/p>\n

\u00ab A potential first and only preventative HIV vaccine, developed by Dr. Chil-Yong Kang\u00a0and his team at The University of Western Ontario, has received approval by the United\u00a0States Food and Drug Administration (USFDA) to start human clinical trials this month\u00a0south of the border.\u00a0With the support of Sumagen Canada, and based on a genetically modified killed whole\u00a0virus, the vaccine holds tremendous promise, having already proven to stimulate strong\u00a0immune responses in preliminary toxicology tests with no adverse effects or safety\u00a0risks.<\/p>\n

With the USFDA holding the most stringent approval requirements, Kang chose to go\u00a0this route with the only HIV vaccine currently under development in Canada – and one of\u00a0only a few in the world.\u00a0\u201cFDA approval for human clinical trials is an extremely significant milestone for our\u00a0vaccine, which has the potential to save the lives of millions of people around the world\u00a0by preventing HIV infection,\u201d says Kang, a researcher and professor at Western\u2019s\u00a0Schulich School of Medicine & Dentistry.\u00a0HIV\/AIDS has killed more than 28 million people worldwide, and more than 35 million\u00a0people currently live with the virus. Since the virus was first characterized in 1983,\u00a0there have been numerous trials through pharmaceutical companies and academic\u00a0institutions around the world to develop vaccines; however, no commercialized vaccine\u00a0has been developed to date.\u00a0Other vaccines evaluated through human clinical trials have focused on either one\u00a0specific component of HIV as an antigen, genetic vaccine using recombinant DNA, or\u00a0recombinant viruses carrying the HIV genes. Kang\u2019s vaccine is unique in that it uses a\u00a0killed whole HIV-1, much like the killed whole virus vaccines for polio, influenza, rabies\u00a0and hepatitis A.\u00a0The HIV-1 is genetically engineered so it is non-pathogenic and can be produced in\u00a0large quantities.\u00a0\u201cThis joint venture between Sumagen and Western is a prime example of what\u00a0collaboration between private industry and university researchers can achieve,\u201d says\u00a0Western president Amit Chakma. \u201cDr. Kang and his team are to be commended for their
\nexceptional talent and remarkable persistence in developing a vaccine that addresses a\u00a0tragic health crisis affecting millions of people around the globe.\u201d\u00bb\u00a0(Source: Western News, 05 Jan.2012.\u00a0The entire text is available at the following link:\u00a0hiv-vaccine-heads-to-human-clinical-trials<\/a>)<\/p>\n

Any African reader of this information may ask himself several questions regarding the attitude of the scientific community. Indeed, since several years, a (late) Cameroon researcher, Professor Victor Anomah Ngu declared to have invented a vaccine. He also called for open confrontation with the scientific community and to a public evaluation of his vaccine. It is really surprising that no particular attention has been paid to his discoveries so far. After the publication of the FDA’s decision authorizing the Canadian research team to carry on testings on humans, \u00a0we contacted Prof. Anomah Ngu’s team in Yaound\u00e9 (Cameroun) with the intention to learn more about the state of their research and particularly about the originality of the Canadians’ discouveries when compared to their vacinne \u00a0Vanhivax<\/span>. We have received no answer from the Camerounian research team.<\/p>\n

About Vahnivax, following information could be read from the website of Prof. Anomah Ngu’s Clinic:\u00a0<\/strong><\/span><\/p>\n

Vanhivax is not a drug so the virus cannot become resistant to it. The auto-vaccine is elaborated from the blood of each individual patient.<\/p>\n

Because the vaccine is not toxic, there are no significant side effects (ie\u2014damage to the organic body). A mild fever, headache, or tenderness in the area of the injection is all one is likely to experience. Whereas the virus increases in strength with the drugs over time, the auto-vaccination treatment of Vanhivax strengthens the immune system against HIV.<\/p>\n

Vanhivax seeks to create a healthy immune system, based on the body\u2019s own defenses. In most cases the body can then mount an effective immune response against the virus. It\u2019s the body\u2019s own perfect medicine.<\/p>\n

Since every organism reacts differently, the dosage of Vanhivax varies greatly. As Dr. Bisong of the Clinic says, \u201cThe vaccine is like a train rolling down its tracks. It has its own momentum, its own power, and if you give the patient an extra dose of the vaccine, it could derail the whole process. Most people want as many treatments as possible but the body and the vaccine don\u2019t work that way.\u201d<\/p>\n

Victor Anomah Ngu \/ Founder of the Clinic of Hope:
\nNow, as far as Vanhivax is concerned and the virus, the vaccine does not act on the virus directly. It doesn\u2019t. It acts on the immune system and the immune system then acts on the virus. \u00bb<\/p>\n

For details on the researches of late Prof. Victor Anomah Ngu:\u00a0<\/span><\/p>\n

Clinique de L\u2019Espoir.<\/span>
\n BP. 11775, Yaounde, Cameroon<\/span>
\n Telephone: +237 222 4189<\/span>
\n Tel\/Fax +237 220 2786<\/span>
\nWeb: www.cellularwisdom.org<\/a>
\nContact us: cellularwisdom.org@gmail.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

According to information made available by canadian media recently, researchers are now heading towards a vaccine. \u00ab A potential first and only preventative HIV vaccine, developed by Dr. Chil-Yong Kang\u00a0and his team at The University of Western Ontario, has received approval by the United\u00a0States Food and Drug Administration (USFDA) to start human clinical trials this […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[],"class_list":["post-2152","post","type-post","status-publish","format-standard","hentry","category-medical-science"],"_links":{"self":[{"href":"https:\/\/africa-and-science.com\/index.php?rest_route=\/wp\/v2\/posts\/2152"}],"collection":[{"href":"https:\/\/africa-and-science.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/africa-and-science.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/africa-and-science.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/africa-and-science.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2152"}],"version-history":[{"count":8,"href":"https:\/\/africa-and-science.com\/index.php?rest_route=\/wp\/v2\/posts\/2152\/revisions"}],"predecessor-version":[{"id":2176,"href":"https:\/\/africa-and-science.com\/index.php?rest_route=\/wp\/v2\/posts\/2152\/revisions\/2176"}],"wp:attachment":[{"href":"https:\/\/africa-and-science.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/africa-and-science.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/africa-and-science.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}